Clinical Trial Update: Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the dose of Zongertinib used alone or with other therapies in HER2-positive metastatic cancers, including breast, gastric, gastroes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Beamion BCGC-1
• Zongertinib (Zongertinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING